These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23238158)

  • 21. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
    Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
    AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of BOLD cerebrovascular reactivity mapping and DSC MR perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors.
    Pillai JJ; Zacà D
    Technol Cancer Res Treat; 2012 Aug; 11(4):361-74. PubMed ID: 22376130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.
    Saraswathy S; Crawford FW; Lamborn KR; Pirzkall A; Chang S; Cha S; Nelson SJ
    J Neurooncol; 2009 Jan; 91(1):69-81. PubMed ID: 18810326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perfusion MR imaging in gliomas: comparison with histologic tumor grade.
    Lee SJ; Kim JH; Kim YM; Lee GK; Lee EJ; Park IS; Jung JM; Kang KH; Shin T
    Korean J Radiol; 2001; 2(1):1-7. PubMed ID: 11752962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
    She D; Xing Z; Cao D
    J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.
    Juan-Albarracín J; Fuster-Garcia E; Pérez-Girbés A; Aparici-Robles F; Alberich-Bayarri Á; Revert-Ventura A; Martí-Bonmatí L; García-Gómez JM
    Radiology; 2018 Jun; 287(3):944-954. PubMed ID: 29357274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
    Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
    Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death.
    Colen RR; Wang J; Singh SK; Gutman DA; Zinn PO
    Radiology; 2015 Apr; 275(1):215-27. PubMed ID: 25490189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of first-pass and second-bolus dynamic susceptibility perfusion MRI in brain tumors.
    Spampinato MV; Wooten C; Dorlon M; Besenski N; Rumboldt Z
    Neuroradiology; 2006 Dec; 48(12):867-74. PubMed ID: 17013587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
    Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
    Mangla R; Singh G; Ziegelitz D; Milano MT; Korones DN; Zhong J; Ekholm SE
    Radiology; 2010 Aug; 256(2):575-84. PubMed ID: 20529987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion.
    Law M; Brodsky JE; Babb J; Rosenblum M; Miller DC; Zagzag D; Gruber ML; Johnson G
    J Magn Reson Imaging; 2007 Jun; 25(6):1113-9. PubMed ID: 17520715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
    Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
    Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?
    Danchaivijitr N; Waldman AD; Tozer DJ; Benton CE; Brasil Caseiras G; Tofts PS; Rees JH; Jäger HR
    Radiology; 2008 Apr; 247(1):170-8. PubMed ID: 18372467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
    Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
    Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
    Law M; Yang S; Babb JS; Knopp EA; Golfinos JG; Zagzag D; Johnson G
    AJNR Am J Neuroradiol; 2004 May; 25(5):746-55. PubMed ID: 15140713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features.
    Gevaert O; Mitchell LA; Achrol AS; Xu J; Echegaray S; Steinberg GK; Cheshier SH; Napel S; Zaharchuk G; Plevritis SK
    Radiology; 2014 Oct; 273(1):168-74. PubMed ID: 24827998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reproducibility of rCBV in glioblastomas using T2*-weighted perfusion MRI: an evaluation of sampling, normalization, and experience.
    Yüzkan S; Mutlu S; Karagülle M; Şam Özdemir M; Özgül H; Arıkan MA; Koçak B
    Diagn Interv Radiol; 2024 Mar; 30(2):124-134. PubMed ID: 37789677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.